Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis.
about
Fingolimod in the treatment of relapsing-remitting multiple sclerosis: long-term experience and an update on the clinical evidencePharmacological Approaches to Delaying Disability Progression in Patients with Multiple SclerosisThe Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple SclerosisBrain MRI atrophy quantification in MS: From methods to clinical application.Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.Effect of Fingolimod on Brain Volume Loss in Patients with Multiple Sclerosis.Defining Disease Activity and Response to Therapy in MS.Detection and quantification of regional cortical gray matter damage in multiple sclerosis utilizing gradient echo MRI.Active brain changes after initiating fingolimod therapy in multiple sclerosis patients using individual voxel-based analyses for diffusion tensor imaging.Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA.Regulation of human glia by multiple sclerosis disease modifying therapies.Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis.Structural Brain Imaging in People With Low Back Pain.Serum retinol levels are associated with brain volume loss in patients with multiple sclerosis."No evident disease activity": The use of combined assessments in the management of patients with multiple sclerosis.Brain Atrophy as a Measure of Neuroprotective Drug Effects in Multiple Sclerosis: Influence of Inflammation.Fingolimod induces neuroprotective factors in human astrocytes.Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis.Validating the use of brain volume cutoffs to identify clinically relevant atrophy in RRMS.Evidence of progressive tissue loss in the core of chronic MS lesions: A longitudinal DTI study.Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study).Objectively measured sedentary behavior and brain volumetric measurements in multiple sclerosis.Defining brain volume cutoffs to identify clinically relevant atrophy in RRMS.Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study.The relationship between the rate of brain volume loss during first 24 months and disability progression over 24 and 48 months in relapsing MS.Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study.Multiple sclerosis seen through new eyes.
P2860
Q26752466-FAD212B5-D9BB-495E-B3A1-EC40C785E2ABQ27000269-1D14A4CD-76AD-408C-BA80-53709A31D0A3Q28073377-E931F14C-68B1-4068-A08C-1B34579CCE0DQ31149648-44A5DDB7-E018-4B79-81EF-76C39B22415BQ35846504-AF57ED8C-A544-414C-A19C-9A287A62D561Q36293431-9004D078-3B5D-46C8-BD86-52933F28DDBEQ36357501-86651B01-B7A1-4FFA-A01E-D54671DD05C6Q37004557-1FE6AB37-31AF-4D8E-9996-2EC9B918B833Q37507448-EEF7C1E2-76BC-4C5B-BA07-86D7C1007631Q38371842-31646262-6BF4-4FA6-BBC4-4D1ACE1AACC6Q38563863-53423AC2-0CC4-45BB-B671-21B2BDF63DE3Q38606914-1BC84F34-30AA-47C1-91D4-D1338A5B9E3CQ39159351-C500B838-72B4-422B-8F9E-E4456B16C73AQ41078810-2D54FB2B-3B06-4C1A-8704-CED49127C15CQ41185260-19219104-156D-4B42-BB32-9486E6C5CB89Q41490523-F7D55CA9-F54A-4C98-A80E-76D1DBE3C36BQ41576345-116C9E80-EDD5-440E-A53E-EE2558B5700CQ47198260-E9B9772B-7834-4443-8C8A-6B376F0765A6Q47445376-BA6593CA-7082-4929-81B0-1B1F22CB5A19Q47547571-9EF14ABB-213B-49A5-A711-82595E59AAB9Q48004049-CAB9CD18-F012-46EE-B844-7A719D8FD6FFQ48363272-F9D5F398-F478-4F4E-924A-8C37D70E9F73Q48625365-A456DF25-CBF0-4ECC-8A21-03A307B94CE4Q49180693-2941B7D0-799A-467A-815F-3EAE46D39362Q52146842-ABABF8AE-1C65-4781-BB0A-1D7B08E4B508Q52645792-633FB834-95B4-4967-8E85-6CB8858AD57CQ53534654-46A98D9E-FACC-479F-870B-3EDEEFEC2D63
P2860
Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Correlation between brain volu ...... utcomes in multiple sclerosis.
@ast
Correlation between brain volu ...... utcomes in multiple sclerosis.
@en
type
label
Correlation between brain volu ...... utcomes in multiple sclerosis.
@ast
Correlation between brain volu ...... utcomes in multiple sclerosis.
@en
prefLabel
Correlation between brain volu ...... utcomes in multiple sclerosis.
@ast
Correlation between brain volu ...... utcomes in multiple sclerosis.
@en
P2093
P2860
P50
P1433
P1476
Correlation between brain volu ...... utcomes in multiple sclerosis.
@en
P2093
Ana de Vera
Dieter A Häring
Ernst-Wilhelm Radue
Gordon Francis
Jeffrey A Cohen
Jeremy R Bright
Philipp von Rosenstiel
P2860
P304
P356
10.1212/WNL.0000000000001281
P407
P577
2015-01-28T00:00:00Z